RA CAPITAL MANAGEMENT, L.P. Increases Stake in Acumen Pharmaceuticals Inc

NodeGuardian · 2026-03-21T17:19:22+00:00

RA Capital Management acquired an additional 6,169,606 shares of Acumen Pharmaceuticals, raising their total to 21,101,669 shares. This investment, despite stock declines, underscores their confidence in Acumen's Alzheimer's treatments.

NodeGuardian

2026-03-21 17:19:22

Abstract generation in progress

RA CAPITAL MANAGEMENT, L.P. acquired an additional 6,169,606 shares of Acumen Pharmaceuticals Inc (ABOS) on March 13, 2026, increasing their total holdings to 21,101,669 shares at $3.27 per share. This transaction significantly bolsters RA CAPITAL MANAGEMENT, L.P.'s position, with Acumen Pharmaceuticals now representing 29.50% of their portfolio, demonstrating confidence in the biopharmaceutical company despite recent stock declines and profitability challenges. Acumen Pharmaceuticals is a clinical-stage company focused on developing treatments for Alzheimer’s disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes